Citations

Mayo Clinic

Showing 10 of 108523 citations.

Further Guaianolides from Amphoricarpos neumayeri ssp. murbeckii from Montenegro
Djordjević, Iris , Jadranin, Milka , Vajs, Vlatka, Menković, Nebojŝa, Tešević, Vele , Milosavljević, Slobodan , Macura, Slobodan

Zeitschrift für Naturforschung B | February 16, 2015 | Volume: 61 | Issue: 11 | Pages: 1437-1442

10.1515/znb-2006-1119 Get It

The aerial parts of Amphoricarpos neumayeri ssp. murbeckii afforded eleven guaianolides with the same relative (1αH,4β H,5αH,7αH) configuration of the basic skeleton. All of them contained a CH2OX (X = H, acetyl or isovaleroyl) group in 4α-position, typical for amphoricarpolides. Four compounds (1 - 4) were isolated before from the same species, originating from different localities. Guaianolides 5 - 11 are new compounds. Compounds 7 and 8 were epoxidized at the 10α(14)-position. Instead of the Δ11(13)-double bond, observed in all previously isolated guaianolides from the same species, the four lactones contained 11α,13-diol (8 - 10) or 11α-OH,13-chloro (11) moieties respectively.
Structured handoff checklists improve clinical measures in patients discharged from the neurointensive care unit
Kramer, Neha M. , Fabris, Rachel R., Burkholder, David B. , Klaas, James P. , Graff‐Radford, Jonathan , Moore, S. Arthur, Jones, Lyell K. , Coon, Elizabeth A. , Wijdicks, Eelco F. M. , Britton, Jeffrey W. , Burkholder, David B , Jones, Lyell K

Neurology Clinical Practice | February 16, 2015 | Volume: 5 | Issue: 1 | Pages: 42-49

10.1212/cpj.0000000000000094 | PMID 29443183 Get It

Acupuncture in the Postoperative Setting for Breast Cancer Patients: A Feasibility Study
Mallory, Molly J., Croghan, Katrina, Sandhu, Nicole P. , Lemaine, Valérie, Bauer, Brent A. , Cha, Stephen S., Croghan, Ivana T. , Degnim, Amy C. , Cha, Stephen S.

The American Journal of Chinese Medicine | February 16, 2015 | Volume: 43 | Issue: 01 | Pages: 45-56

10.1142/s0192415x15500032 | PMID 25682785 Get It

Acupuncture is used to treat a variety of symptoms and conditions associated with cancer and cancer treatments. The present study was performed to evaluate the feasibility of providing acupuncture in the hospital setting for breast cancer patients and to evaluate the short-term effect of acupuncture on stress, anxiety, and pain. This was an open label study conducted at Mayo Clinic Hospital, Methodist and Saint Marys Campus, Rochester, Minnesota. A total of 20 adult breast cancer patients undergoing mastectomy and/or breast reconstruction were recruited and offered daily acupuncture intervention beginning postoperative day 1 and continuing for the duration of the hospital stay. Outcome measures included the Symptom Visual Analog Scale (VAS) and Satisfaction Question and Was-it-Worth-it (WIWI) Questionnaire. It was found that acupuncture is a feasible option for postoperative breast cancer patients. In addition, it can significantly decrease the levels of anxiety (p = 0.0065), tension/muscular discomfort (p < 0.001) and pain (p = 0.023). The association between acupuncture and relaxation was found to be statistically borderline (p = 0.053). This feasibility study showed that acupuncture can be integrated into a busy postsurgical clinical practice. These results also suggest that acupuncture may be an important intervention in the postoperative setting for breast cancer patients.
Combat-Related Intradural Gunshot Wound to the Thoracic Spine: Significant Improvement and Neurologic Recovery Following Bullet Removal
Louwes, Thijs M, Ward, William H. , Lee, Kendall H. , Freedman, Brett A.

Asian Spine Journal | February 16, 2015 | Volume: 9 | Issue: 1 | Pages: 127

10.4184/asj.2015.9.1.127 | PMID 25705346 Get It

Overcoming the Challenges of Studying Uterine Fibroids
Laughlin-Tommaso, Shannon K.

Journal of Women's Health | February 15, 2015 | Volume: 24 | Issue: 2 | Pages: 112-113

10.1089/jwh.2015.1520 | PMID 25682815 Get It

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis
Barbui, Tiziano , Carobbio, Alessandra , Thiele, Jürgen, Rumi, Elisa , Gisslinger, Heinz , Rodeghiero, Francesco, Randi, Maria Luigia , Rambaldi, Alessandro , Pieri, Lisa , Pardanani, Animesh , Passamonti, Francesco , Tefferi, Ayalew , Vannucchi, Alessandro M. , Finazzi, Guido , Rambaldi, Alessandro , Passamonti, Francesco

American Journal of Hematology | February 14, 2015 | Volume: 90 | Issue: 5 | Pages: 434-437

10.1002/ajh.23970 | PMID 25683038 Get It

Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time‐dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO‐defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P < 0.0001) and older age (P = 0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post‐2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV. Am. J. Hematol. 90:434–437, 2015. © 2015 Wiley Periodicals, Inc.
Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation
Mendoza, Neil, Noël, Pierre, Blair, Janis E.

Transplant Infectious Disease | February 14, 2015 | Volume: 17 | Issue: 3 | Pages: 380-388

10.1111/tid.12372 | PMID 25682795 Get It

AbstractBackgroundAllogeneic hematopoietic stem cell transplant (allo‐HSCT) recipients have multiple risk factors for coccidioidomycosis, and previous reports of coccidioidomycosis in this patient population describe severe infections with poor outcomes.MethodsWe performed a retrospective chart review of allo‐HSCT recipients with active coccidioidomycosis to characterize the utility of diagnostic tests for coccidioidomycosis and to determine treatment outcomes.ResultsEleven of 426 (2.6%) allo‐HSCT recipients experienced active coccidioidomycosis after transplantation. Of these 11 patients, 1 (9%) had extrapulmonary infection, 9 (82%) patients were hospitalized, and 5 (45%) died. Culture or histology was positive in 33% (3/9) of the patients tested. Most (64% [7/11]) had at least 1 positive serologic test result, and the enzyme immunoassay immunoglobulin G test was positive most often (overall 55% [6/11]). Chest radiographs and chest computed tomography scans showed miliary or multifocal nodular infiltrates or consolidations, consistent with coccidioidomycosis, in 80% (8/10) and 100% (9/9), respectively, of patients tested throughout the course of active illness. Rapid polymerase chain reaction testing was positive in 71% (5/7) of the patients tested. Peripheral eosinophilia was present in 18% (2/11) of patients.ConclusionCoccidioidomycosis is associated with high morbidity and mortality in allo‐HSCT recipients in an area endemic for Coccidioides. Diagnosis of this infection can be difficult and often requires multiple and frequently invasive tests. Antifungal prophylaxis should be considered for patients at highest risk.
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Reeder, Craig B. , Libby, Edward N., Costa, Luciano J. , Bergsagel, P. Leif , Mayo, Angela, Reddy, Sravan , Gano, Katherine, Dueck, Amylou C. , Stewart, A. Keith, Bergsagel, P. Leif , Mikhael, Joseph R., Mıkhael, Joseph , Buadi, Francis K. , Dueck, A. C. , Costa, Luciano J

British Journal of Haematology | February 14, 2015 | Volume: 169 | Issue: 2 | Pages: 219-227

10.1111/bjh.13296 | PMID 25683772 Get It

SummarySixty‐four transplant‐eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m2 cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1–28) and 40 mg dexamethasone (days 1, 8, 15, 22) in 28‐day cycles (CYKLONE regimen). Carfilzomib was dose‐escalated to 15/20, 20/27, 20/36 and 20/45 mg/m2 to determine the maximum tolerated dose (MTD), which was 20/36 mg/m2. Regardless of attribution, common Grade 3 or higher adverse events were lymphopenia (38%), neutropenia (23%) and anaemia (20%). All peripheral neuropathy (31%) was Grade 1 and considered most likely to be thalidomide‐related. Common cardiac or pulmonary events of any grade in ≥5% of patients included dyspnoea (20%) and cough (6%). Overall (N = 64), 91% of patients achieved a best response of partial response or better across all cycles of treatment, including five patients with complete responses. At the MTD (n = 29), 59% of patients achieved a very good partial response or better after four cycles (primary end point). Stem cell collection was successful in all patients in whom it was attempted (n = 42). Progression‐free survival and overall survival at 24 months was 76% and 96%, respectively (median follow‐up of 17·5 months). CYKLONE appears highly efficacious in NDMM patients, with manageable toxicities.
Lack of Effect of Metformin on Mammary Carcinogenesis in Nondiabetic Rat and Mouse Models
Thompson, Matthew D. , Grubbs, Clinton J., Bode, Ann M. , McGovern, Renee M., Bernard, Philip S., Stijleman, Inge J., Green, Jeffrey E., Bennett, Christina N., Juliana, M. Margaret, Moeinpour, Fariba, Steele, Vernon E., Lubet, Ronald A. , Reid, Joel M. , McGovern, Renee, Green, Jeffrey E.

Cancer Prevention Research | February 14, 2015 | Volume: 8 | Issue: 3 | Pages: 231-239

10.1158/1940-6207.capr-14-0181-t | PMID 25681088 Get It

Abstract Epidemiologic studies have shown that diabetics receiving the biguanide metformin, as compared with sulfonylureas or insulin, have a lower incidence of breast cancer. Metformin increases levels of activated AMPK (AMP-activated protein kinase) and decreases circulating IGF-1; encouraging its potential use in both cancer prevention and therapeutic settings. In anticipation of clinical trials in nondiabetic women, the efficacy of metformin in nondiabetic rat and mouse mammary cancer models was evaluated. Metformin was administered by gavage or in the diet, at a human equivalent dose, in standard mammary cancer models: (i) methylnitrosourea (MNU)-induced estrogen receptor–positive (ER+) mammary cancers in rats, and (ii) MMTV-Neu/p53KO ER− (estrogen receptor–negative) mammary cancers in mice. In the MNU rat model, metformin dosing (150 or 50 mg/kg BW/d, by gavage) was ineffective in decreasing mammary cancer multiplicity, latency, or weight. Pharmacokinetic studies of metformin (150 mg/kg BW/d, by gavage) yielded plasma levels (Cmax and AUC) higher than humans taking 1.5 g/d. In rats bearing small palpable mammary cancers, short-term metformin (150 mg/kg BW/d) treatment increased levels of phospho-AMPK and phospho-p53 (Ser20), but failed to reduce Ki67 labeling or expression of proliferation-related genes. In the mouse model, dietary metformin (1,500 mg/kg diet) did not alter final cancer incidence, multiplicity, or weight. Metformin did not prevent mammary carcinogenesis in two mammary cancer models, raising questions about metformin efficacy in breast cancer in nondiabetic populations. Cancer Prev Res; 8(3); 231–9. ©2015 AACR.
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non‐muscle‐invasive bladder cancer
Cockerill, Patrick, Knoedler, John, Frank, Igor, Tarrell, Robert F., Karnes, R. Jeffrey , Cockerill, Patrick A, Knoedler, John J., Tarrell, Robert, Karnes, Robert J

BJU International | February 13, 2015 | Volume: 117 | Issue: 3 | Pages: 456-462

10.1111/bju.13088 | PMID 25682834 Get It

Objectives To evaluate oncological outcomes after combination intravesical therapy with gemcitabine ( GC ) and mitomycin C ( MMC ) in the setting of recurrent non‐muscle‐invasive bladder cancer ( NMIBC ) after failure of previous intravesical therapy. Patients and Methods We retrospectively identified patients with recurrent NMIBC after previous intravesical therapy, who refused or were not candidates for cystectomy, between 2005 and 2011. GC and MMC were sequentially instilled weekly for 6–8 weeks. Data were collected regarding patient demographics, bladder cancer history, and number and type of intravesical therapies before GC / MMC . Outcomes evaluated included time to recurrence and/or progression after GC / MMC . Recurrence‐free outcomes were estimated using the Kaplan–Meier method, and Cox proportional hazards regression models were used to test the association of clinicopathological features with outcomes. Results In all, 27 patients were identified, 23 with high‐risk disease (high‐grade or carcinoma in situ ) and four with intermediate‐risk disease (multifocal or recurrent low‐grade). All patients received prior intravesical therapy, and 17 patients (63%) received multiple courses. Twenty‐four patients were treated with BCG . The median (range) disease‐free survival of all patients was 15.2 (1.7–39.3) months. Seventeen patients (63%) developed recurrent bladder cancer, a median of 15.2 months after therapy. One patient progressed to muscle‐invasive disease 5 months after treatment, and one developed metastatic disease 22 months after treatment. Three patients went on to cystectomy. Ten patients (37%) had no evidence of disease at last follow‐up, with a median follow‐up of 22.1 months. Conclusion The combination of intravesical GC and MMC could offer durable recurrence‐free survival to some patients with recurrent NMIBC who are not candidates for, or refuse, cystectomy.